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Absolute or relative effects? Arm-based
synthesis of trial data
S. Dias* and A. E. Ades
We congratulate Hwanhee Hong and colleagues on another fascinating paper (Hong et al., 2015a) arguing the
case for arm-based models for meta-analysis.
The standard approach to meta-analysis is the contrast-based model where the information that is pooled over
trials is the information of the trial-speciﬁc relative treatment effect, expressed for example as a log relative risk,
log odds ratio, or as a mean treatment difference. In an arm-based model, it is the absolute log risk, log odds,
or mean outcome on each arm that are pooled.
There is no doubt that arm-based models are an intriguing alternative to the accepted understanding of meta-
analysis, and that they provide a very elegant alternative approach to network meta-analysis (NMA). However,
readers of Research Synthesis Methods (RSM) will have no difﬁculty in recognising that arm-based models represent
a radical – even revolutionary – departure from current meta-analytic practice.
In this commentary, we begin by outlining the key differences between arm- and contrast-based meta-analysis
to make clear the true extent of the implications of the claims being made. We then argue that contrast based
models are to be preferred on both theoretical and practical grounds.
Hong and colleagues present a number of arguments about the core assumptions of contrast-based models,
both in their RSM paper (Hong et al., 2015a) and previously (Zhang et al., 2014, Ohlssen et al., 2014, Zhang
et al., 2015, Hong et al., 2015b), which we believe are mistaken. We offer some counter-arguments and comment
on the simulation study presented by Hong et al. (2015a).
1. Classic contrast-based, contrast-based plus baseline and arm-based models
Hong et al. (2015a) contrast three kinds of models. We will call these (a) the “Classic Contrast-Based” (Classic CB)
model, which corresponds to the standard model for pair-wise meta-analysis (Higgins and Green, 2008), extended
to NMA (Higgins and Green, 2008, Dias et al., 2013a, Lu and Ades, 2004, Cooper et al., 2009, Lu and Ades, 2006,
Caldwell et al., 2005), (b) “Contrast-Based plus Baseline” (CB + Baseline), and (c) “Arm Based” (AB). It is important
to be clear about notation and terminology, so we start with pair-wise meta-analysis and then turn to NMA.
With the contrast-based models, particularly those used in a frequentist framework, the data to be pooled are
the relative effect measures, and in its most common implementation the absolute effects are not even available
to estimate. Indexing trials by i, the data Di,XY are the observed relative effect measures comparing treatment Y to
X, δi,XY, which in a Bayesian setting are the “shrunken” trial-speciﬁc estimates, and dXY are the mean relative effects.
Thus, the “Classic CB” model for pair-wise (two-treatment) data is stated as follows:
Di;XYeN δi;XY ; ; Vi;XY  }Classic CB} model with differencebased likelihood
δi;XYeN dXY ; σ2XY : (1)
Arm-based likelihoods (not to be confused with arm-based models) have also been proposed (Prevost et al.,
2000, Smith et al., 1995) particularly in a Bayesian context, partly because they avoid normal approximations for
count data. This obliges us to introduce the parameter μi,X representing the absolute effect of the control arm
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X, on the appropriate scale (log risk, log odds, etc). The scale is determined by the link function G which transforms
the relative effect parameter of interest, Θi,XY (for example a probability or rate), onto a scale where its effects can
be assumed to be additive:
G Θi;XY
  ¼ αi;XY ¼ μiX þ δiXY CB model with arm-based likelihood: (2)
This form of contrast based model has always come in two ﬂavours (Prevost et al., 2000). The one that
corresponds exactly to the “Classic CB” model (1) treats the μi,X as unrelated nuisance parameters. This is the
approach adopted in the NMA models developed in Bristol (Dias et al., 2013a, Lu and Ades, 2004, Prevost et al.,
2000).
The alternative is to put another hierarchical model on the trial-speciﬁc control-arms: μi;XeN mX ; σ2m  (Achana
et al., 2013, Dias et al., 2013c). This is the “CB+baseline model”, or alternatively a bivariate normal model on
the μi,X and the δi,XY could be adopted (van Houwelingen et al., 1993).
To see how this idea works in NMA, we need to complicate the notation a little. First, we will consider trial-
speciﬁc treatment indices k= 1, 2, 3…, and we distinguish between the relative effect of the k-th treatment
relative to the control treatment on that trial δi;t1tk , and its effect relative to the reference treatment 1, δi;1tk , which
may or may not be present in trial i. With this extended notation, the “Classic CB” model makes the trial-speciﬁc
control arms arbitrary and unrelated.
G Θi;tk
  ¼ αi;tk ¼ μit1 þ δi;t1tk ; μit1eN 0; 1002  Classic CB model for NMA (3)
Note that often, subscript t1 is dropped from μit1 , as it is redundant. Clearly, there is no way of estimating an
absolute effect for any treatment from the “Classic CB” model.
We note in passing that in another paper Hong et al. (2015b) claim that the assumption of exchangeability of
“effects relative to an arbitrary and nonconstant baseline remains much to assume”. This misses the point that
exchangeability of the effects δi,1k relative to treatment 1 implies exchangeability of all the δi,jk (Lu and Ades, 2009).
In the “CB+baseline” model, a model is placed on the absolute effect of reference treatment 1 in trial i. Note
that it is not put on the trial control arms, as these are not necessarily the same treatment—care should be taken
that only the effect of treatment 1 is modelled. This allows absolute effects on the chosen scale (for example the
log-odds or log), ak, to be calculated for any treatment based on the included trial data. Themodel can be written as
G Θi;tk
  ¼ αi;tk ¼ μi1 þ δi;t1tk ; μi1eN m; σ2m  CBþ baseline model f or NMA
ak ¼ mþ d1tk :
(4)
Note that in the “CB+baseline”model, information on the baseline will back-propagate onto the relative effect
parameters. It is this property of “CB+ Baseline” models that makes the relative effect estimates vulnerable to
misspeciﬁcation of the absolute effects.
We can now set out the arm-based models proposed by Hong et al. (2015a) as
G Θi;tk
  ¼ αi;tkeN atk ; σ2tk
 
AB model for NMA: (5)
The ﬁrst feature we notice is that there are no relative treatment effects in equation (5). Mean “treatment
effects” on the linear predictor scale are manufactured from the treatment-speciﬁc means as dXY= aY aX. Note
that while the CB modeller working on binary data is committed to specify whether effects are additive on a
continuous, log, or log-odds scale, the AB modeller is free to report risk differences, G 1(aY)G 1(aX), relative
risks G 1(aY)/G
 1(aX), or odds ratios (G
 1(aY)G
 1(1 aX))/(G 1(aX)G 1(1 aY)). For binary outcomes, both probit
and logit link functions have been proposed in arm-based models, presumably giving virtually identical results.
This “model-free” approach to relative effect estimation has the advantage that it makes no assumptions, but,
as we see below, it comes with a heavy price in posterior variance of the relative effects.
In the latest paper in RSM Hong et al. (2015a) extend AB modelling to multiple outcomes, and run simulations
that compare “Classic CB”, “CB+baseline”, and “AB” models in various styles. In previous work developing AB
models Zhang et al. (2014) have criticised the “Classic CB” model on the grounds that, because it contains no
model for absolute effects, it cannot report overall event rates without making further assumptions (although
some would see this as an advantage of “Classic CB”). Other papers have examined the concept of inconsistency
in NMA (Zhang et al., 2015) and looked at the role of AB models in drug development (Ohlssen et al., 2014).
1.1. Comparing arm-based and contrast based models
(a) Fundamentals of meta-analysis
Although much of the arm-based literature casts the debate as speciﬁcally relevant to NMA, it should be clear that
the central claim being made is equally relevant to pair-wise (i.e. two-treatment) meta-analysis (MA). The proposal
that one should pool absolute arm effects rather than relative treatment effects goes against the entire tradition of
MA, in which the absolute event rates have been viewed as nuisance parameters, and as highly variable, while the
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relative effects, expressed on a suitable scale, have been seen as relatively stable. One might go further, and say
that arm-based models run against the entire tradition of epidemiological statistics in which relative effects – for
example of risk factors – are pooled in multiple 2-by-2 tables (Mantel and Haenszel, 1959, Zelen, 1971).
We also believe that arm-based pooling effectively breaks randomisation, and in fact runs against the entire
way in which randomised controlled trials are designed, analysed, and used.
While “AB” models take an extreme position, many of us have also argued against “CB+baseline” models,
because, unless the baseline model is correctly speciﬁed, the relative effect estimates will be biased. For example,
one often ﬁnds that outcomes on the control arm have improved over time, because less severe populations are
entered into more recent trials while the relative effect has stayed constant. If one random effects model is put on
the baselines and another on the relative effects, and both are estimated at the same time, we expect the baseline
effects in earlier studies to be shrunk upwards, and relative effects under-estimated, while the relative effects in
more recent studies will be over-estimated. Senn (2010) has argued forcefully against “CB+baseline” models
for these reasons. “AB” models will be even more likely to produce biased treatment effects, if one accepts the
commonly made assumption that it is the relative effects which are exchangeable across trials.
(b) Evidence synthesis for decision-making
Working as we do on evidence synthesis in the decision making context, we are well aware the absolute event
rates often play a more important role than the relative treatment effects when treatment recommendations
are made. Thus, we fully accept that there needs to be a model for the absolute effect that one would see on
at least one of the treatments, from which absolute effects can be recovered for all treatments.
Where we differ from proponents of AB models is that we believe that, while randomised controlled trials are
unquestionably the best data sources to inform relative effects, the data sources that best inform the absolute
effects might be cohort studies, a carefully selected subset of the trials included in the meta-analysis, or expert
opinion. Manufacturers making submissions on new products to the National Institute for Health and Care
Excellence (NICE) in the UK are asked to explain the basis on which they have chosen the evidence for absolute
effects, and this is quite distinct from trial evidence from which relative effects are sourced (National Institute
for Health and Clinical Excellence, 2012).
The disadvantage of an arm based model is that it obliges the modeller to use exactly the same data sources for
both absolute and relative effects, whereas the natural way to carry out health technology assessments of
alternative treatments is to apply a “transportable” relative effect estimate to an independently estimated baseline
model, which can be carefully tailored to represent the relevant target population. This is what is recommended in
standard texts (Hunink et al., 2001, Drummond et al., 1997, National Institute for Health and Clinical Excellence,
2012).
One might add that in many cases the entire debate about whether a treatment should be adopted hinges on
the “threshold” baseline risk at which the treatment – whose relative effect is assumed to remain constant in ratio
terms – becomes cost effective, or at which the clinical beneﬁts outweigh the side-effects. Statin treatment is
perhaps the prime example (Stone et al., 2013, National Clinical Guideline Centre, 2014). It is not clear how an
arm-based approach could be modiﬁed or extended to produce the kind of analysis that is needed to support
decision makers in this context, or indeed in any context.
(c) The empirical question
We are not sure whether proponents of “AB” models would agree, but to some extent the choice between arm-
and contrast based models could be regarded as an empirical question: do we ﬁnd in practice that relative effects,
given that an appropriate scale has been chosen, are more stable than absolute effects? This is the kind of
question that has been studied previously using L’Abbé plots (L’Abbe et al., 1987, Song, 1999).
In the example presented by Hong et al. (2015a), the between study variances in “AB” models were
considerably greater than in the “CB” models. It is important to note that the posterior precision of the mean
relative effects d1k was quite severely degraded as a result, as can be seen from the wide credible intervals of
AB models in Fig. 6. Of course, poor posterior precision is not necessarily inappropriate posterior precision, but
the effect of the arm-based model is to allow the huge variation in absolute effects to affect the estimates of
relative effects, while contrast-based pooling is precisely designed to insulate them from this. Global Goodness
of ﬁt and Deviance Information Criteria do not provide a good basis for model choice as different patterns of
shrinkage can be expected. The choice should be made on principled and empirical grounds, with a view to
minimising bias, not maximising goodness of ﬁt or parsimony.
1.2. Missing-ness of treatment arms in NMA
The key assumption in all the CB models is the exchangeability of the trial-speciﬁc treatment effects δi,XY across the
entire ensemble of trials. Speciﬁcally this means that the δi,XY in XY trials are exchangeable with δi,XY in XZ and YZ
trials and indeed in all the trials, including those that have neither X nor Y arms. In previous papers (Caldwell et al.,
2005, Dias et al., 2011) we have said that this was equivalent to the arms being “missing at random” (MAR). By this
we meant that missing-ness was unrelated to any factors that inﬂuenced the relative treatment effects δi,XY. Hong
et al. (2015a) claim that CB models require “missing completely at random” (MCAR) and will not work with MAR,
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because MAR would rule out missing-ness being related to absolute efﬁcacy. Of course, if “Classic CB” models for
NMA were vulnerable to missing-ness that was related to absolute effects, this would be a most serious criticism
because this type of missing-ness is surely a very common occurrence. But “Classic CB”models are quite obviously
not vulnerable to this kind of missing-ness, because it does not imply that missing-ness depends on relative
effects. The only requirement for CB models is that missing-ness is unrelated to the relative effects, which is related
to the requirement that the trial-speciﬁc relative effects are exchangeable (Lu and Ades, 2009).
Hong et al. (2015a) correctly note that CB models are vulnerable to relationships between relative treatment
effects and baseline severity. In a CB framework this – as with any relative effect modiﬁcation – is typically handled
by a meta-regression of the trial-speciﬁc relative effects against absolute response to the reference treatment, but
without putting a model on the reference treatment (Dias et al., 2013b). What is less clear is how AB modellers
would cope with this pattern in the data. Covariates can readily be added to AB models, but there appears to
be no way of adding a covariate to a relative effect, or putting different covariates on relative and absolute effects.
2. Simulation studies
The simulation studies reported in Hong et al. (2015a) relate to an extension of AB models to multiple outcomes,
and they compare certain variants of AB, and “CB+baseline” models, with “Classic CB” (labelled “LAREhom” in
Hong et al. (2015a), for Lu & Ades Random Effects homogeneous variance). The purpose is to compare the three
models in three-treatment networks under different forms of missing-ness: MCAR (completely at random), MAR,
and MNAR (not at random), and with different degrees of missing-ness, approximately 10%, 20%, and 40%. The
target outputs of the simulations are (a) the arm means a1, a2, a3 and (b) the mean relative effects d12,d13 (an
identity link is used so we ignore the back transformation G1).
Readers should immediately be asking themselves, how can the “Classic CB” model, which does not concern
itself at all with absolute effects be made to generate estimates of the absolute effects a1, a2, a3?! It is at this point
that we must confess that in a number of publications we have, to our eternal regret, created an estimate of a1 by
averaging the absolute event rates on the reference treatment 1. We have done this simply to illustrate the
process by which absolute effects ak can be composed from the relative effects d1k and an estimate of the
absolute effect on the reference treatment that does not originate from the NMA itself. In spite of this tactical
blunder, it should be clear, and we believe it is clear from our speciﬁcation of the “Classic CB” models in previous
publications (Dias et al., 2013c, Lu and Ades, 2004), that these estimates of a1 have nothing to do with the “Classic
CB” relative effects model and they have the effect of allowing us to estimate absolute effects without taking the
risk of introducing bias into the relative effects. We are therefore quite surprised that Hong et al. (2015a) claim that
their simulations show that “Classic CB” “fails to estimate the ak correctly”. The truth is that “Classic CB” has nothing
whatsoever to say about absolute effects at all, and this is perfectly obvious from our publications.
Needless to say, “AB” and “CB+baseline” models both perform well in terms of bias, MSE, and coverage, on ak
in simulations, but, as we explain above, the estimates of ak obtained by these models are unlikely to be of
practical value, unless they happen to best represent the target population. Moreover, it is highly likely that they
will be accompanied by biased estimates of the relative effects d1k. In the case of “AB” models the estimates of ak
are, in our view, completely arbitrary and unusable. They have an interpretation that makes about as much sense
as the average distance between carrots and Cadillacs.
When it comes to the d1k, the simulation studies show that “Classic CB” performs as well as “CB+baseline”
model in MCAR scenarios, and better than “CB+baseline” model for “MAR” and MNAR scenarios. (We put the
MAR in quotes as they are generated from AB models, and we are uncertain as to whether they would be MAR
with respect to relative effects). The main problems for “Classic CB” are the “MAR” scenarios. It is important to
appreciate that all the missing-ness scenarios have the missing-ness of treatments depending on a function of
the simulated absolute effects on one or both of the outcomes. For example in “MAR” the presence of treatment
1 depends on the sum over the two outcomes of the absolute effects on treatment 2, while the presence of
treatment 3 depends on the difference between outcomes on treatment 2. It is not immediately clear what this
implies about missing-ness with respect to relative effects. It is therefore difﬁcult to interpret the results, in which
“Classic CB” performs worse as the degree of missing-ness increases, because the data are generated with
correlations while the “Classic CB” models used to analyse each simulated dataset assume zero correlations. We
note that “Classic CB” models for multiple outcomes which incorporate correlations have been proposed
(Efthimiou et al., 2014, Bujkiewicz et al., 2014, Bujkiewicz et al., 2013, Schmid et al., 2014) and they would perhaps
provide a fairer comparison.
Regarding the MNAR scenarios, Hong et al. (2015a) note that “Classic CB” produces “oddly unbiased” estimates
of the d1k; “oddly” because both a1 and ak are biased, but “to the same degree”. This is, in fact, exactly what would
be expected. A great many MNAR scenarios were tested, in which missing-ness was an extremely complex
function of simulated absolute effects on different treatments and outcomes, but none clearly implying a failure
of MAR on relative effects. We take these results as a vindication of the arguments set out above to the effect that
placing a model on baseline effects makes relative effects vulnerable to misspeciﬁcation of the baseline model.
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3. Conclusions
We believe that AB models are thoroughly misguided, and a huge step back from the separation of absolute and
relative effects that has been at the core of modern epidemiology and biostatistics for so long. The use of AB
models would risk seriously biased estimates of relative treatment effects, with over-inﬂated posterior variance,
and block the ability to “transport” relative effects into new absolute effect scenarios, a basic principle in health
technology assessment.
Absolute effects should be estimated independently, and the appropriate evidence sources are most likely not
to be trials, let alone the same trials which inform the relative effects. The exchangeability assumptions on which
“Classic CB” models are based imply MAR with respect to relative effects, and we remain unconvinced by the
simulation studies so far presented.
The presentations of AB models in RSM and other journals are superb examples of Bayesian data analysis, and
while we disagree profoundly with their assumptions, the authors have succeeded in making us reﬂect more
precisely on the assumptions we are making in evidence synthesis models, and on how well these assumptions
are supported by theory or empirical evidence. One particular issue that their papers raise is scale. Some of the
important beneﬁts enjoyed by CB modellers depend on an appropriate choice of link function, and it is perhaps
not always recognised that choice of which treatment is best can be sensitive to this (Caldwell et al., 2012, van
Valkenhoef and Ades, 2013, Norton et al., 2012). Hong et al.’s presentation of “scale-free” AB models surely
challenges our usually blind adoption of log-odds, log, or even identity links, and it encourages us to pay much
more careful attention to the fundamental properties of both frequency counts in different situations, and the
scales of measurement used for continuous outcomes.
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